Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of HMA and Venetoclax in AML Patients With Negative MRD
NCT06511882Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, decitabine, venetoclax in acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
azacitidinedecitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06511882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511882.